BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, September 22, 2023
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Biopharma money raised: Jan. 1-Aug. 17, 2023

Aug. 18, 2023
No Comments
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma

Aug. 18, 2023
No Comments
Total raised in public, private and other financings of biopharma companies, comparing 2023 vs. 2022 vs. 2021 vs. 2020 vs. 2019.
Read More
Approved stamp
Biopharma regulatory actions and approvals July 2023

US FDA approvals up 20% year-over-year, average 14 a month in 2023

Aug. 18, 2023
By Amanda Lanier
No Comments
Drug approvals by the U.S. FDA increased 20.48% compared to the first seven months of 2022, even with July approvals slightly down to 13 from the previous six months’ average of 14.5 per month. Worldwide approvals from January to July are down 13.8% from the same period last year.
Read More
Concept of business partnership
Biopharma deals July 2023

First seven months of 2023 sees $105.4B in biopharma deals and $37.6B in M&As

Aug. 15, 2023
By Amanda Lanier
No Comments
The June dip in biopharma deal value was short-lived, with July seeing 106 deals worth $17.57 billion, up 72.03% from $10.22 billion in July 2022.
Read More
Green arrow up red arrow down

Med-tech deals reach $8.63B and M&As total $37.33B in first 7 months of 2023

Aug. 14, 2023
By Amanda Lanier
No Comments
Med-tech deal values the first seven months of the year are up more than 50% from last year. Meanwhile, M&As decreased almost 70% from the same time period in 2022.
Read More

Med-tech gainers and losers for Aug. 7-11, 2023

Aug. 14, 2023
No Comments
The top 10 med-tech stock gainers and losers for the week.
Read More

Biggest gainers and losers for Aug. 7-11, 2023

Aug. 14, 2023
No Comments
The top 10 biopharma stock gainers and losers for the week.
Read More

Biopharma money raised: Jan. 1-Aug. 10, 2023

Aug. 11, 2023
No Comments
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma

Aug. 11, 2023
No Comments
Total raised in public, private and other financings of biopharma companies, comparing 2023 vs. 2022 vs. 2021 vs. 2020 vs. 2019.
Read More
Concept of business partnership
Biopharma deals July 2023

First seven months of 2023 sees $105.4B in biopharma deals and $37.6B in M&As

Aug. 11, 2023
By Amanda Lanier
No Comments
The June dip in biopharma deal value was short-lived, with July seeing 106 deals worth $17.57 billion, up 72.03% from $10.22 billion in July 2022. In the first seven months of 2023, 778 deals were completed worth $105.39 billion, compared to 995 deals worth $105.9 billion in the same period last year, a decrease of 0.48% by value and a decrease of 21.8% by volume. The same timeframe in 2021 saw 1,240 deals valued at $107 billion, 1,228 deals worth $112.23 billion in 2020, and 963 deals totaling $93.39 billion in 2019.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 173 174 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing